Dr Christopher George
Prosiectau fel Prif Ymchwiliwr
- Industry-oriented development of new predictive cardiotoxicity drug screening assay (01.01.2016 - 31.07.2016)
- Investigations into the non-thermal response of cardiomyocytes in applied electromagnetic fields (01.08.2016 - 31.01.2017)
- Targeted stabilisation of human cardiac ryanodine receptors as a therapeutic strategy for cardiac disease (01.10.2009 - 30.09.2014)
- The development of a novel cardiomyocyte-based high throughput screening (HTS) bioassay for identifying new anti arrhythmics (01.07.2008 - 30.06.2012)
Prosiectau fel Cyd-Ymchwiliwr
- Modulating ryanodine receptor-mediated calcium release to alleviate calcium leak during diastole (04.08.2014 - 03.02.2016)
- Predicting anti-arrhythmic drug efficacy from the divergent molecular basis of ryr2 dysfunction in genetic arrhythmia syndromes (01.10.2015 - 30.09.2020)
- Uncovering the mechanisms involved in the block of Ca2+ release from the cardiac sarcoplasmic reticulum by flecainide (01.01.2012 - 30.06.2014)